Magnetar Access & Blossom present
Reimbursement Pathways
for Psychedelic Therapies
Charting psychedelic therapy's path to European
healthcare coverage and mental health transformation.
Unlocking Reimbursement for Psychedelic Therapies
Psychedelic therapies show great potential for treating mental health conditions,
but challenges in regulatory approval, reimbursement models, and healthcare system
integration create significant access barriers.
Our report explores the current landscape,
identifies key obstacles, and presents actionable solutions to improve accessibility
and affordability across Europe.
Clinical Promise
Psychedelic therapies show high efficacy in clinical trials for PTSD, depression, and addiction.
Regulatory Challenges
Scheduling restrictions, clinical trial complexities, and policy gaps slow market adoption.
Reimbursement Barriers
High costs, complex treatment models, and lack of payer clarity create funding challenges.
Infrastructure & Training
Healthcare systems need trained therapists, dedicated spaces, and sustainable funding models.
Path Forward
Multi-stakeholder collaboration and policy reform can enable reimbursement and access.
"Attio scales exactly how we need it to. Our entire team has 10x more visibility into our customer relationships, pipeline, and revenue, all in one place."
Jamie Marshall, COO & Co-founder
"The platform provides incredible insights that have transformed how we manage client relationships and track progress."
Alex Johnson, CTO & Co-founder
"We've been able to streamline our processes and improve communication across departments thanks to this innovative solution."
Sam Rodriguez, Head of Operations
Report Resources
The following additional resources provide detailed supporting information, data, and context that complement the main report's findings and analysis.
The Road Ahead
This report provides a foundation for understanding how psychedelic therapies might be integrated into European healthcare systems. However, making these treatments accessible to patients will require sustained collaboration between stakeholders and creative solutions to address implementation challenges. We hope this analysis catalyses further work toward developing practical, sustainable access pathways.
Get Involved
Want to help advance psychedelic therapy access in Europe? Our team collaborates with stakeholders across the healthcare ecosystem to develop practical solutions for psychedelic therapy implementation. Contact us to explore how we can work together.
Work with Us Download the Report